Xikang Pharmaceutical

Xikang Pharmaceutical is a clinical-stage biopharmaceutical company based in Huzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on high-value targets within the DNA damage response (DDR) and tumor immunology pathways to address significant unmet medical needs in cancer treatment. Its lead program, XK003, is a highly selective USP1 inhibitor currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors, particularly those with homologous recombination deficiency. Xikang's pipeline also includes XK001, a potent HPK1 inhibitor designed to enhance the immune system's ability to combat tumors. By leveraging its internal R&D capabilities, the company aims to advance a robust portfolio of targeted therapies from early discovery through commercialization.